|
Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL). |
|
|
Research Funding - Kite, a Gilead company |
|
|
Consulting or Advisory Role - Kite, a Gilead company |
|
|
Consulting or Advisory Role - Forty Seven; Gilead Sciences; Seagen |
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dynavax Technologies (Inst); Genentech (Inst); Gilead Sciences (Inst); Idera (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen Research & Development (Inst); Kite, a Gilead company (Inst); LAM Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Seagen (Inst) |
|
|
Speakers' Bureau - Pharmacyclics; Seagen |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Alexion Pharmaceuticals; Sanofi |
Research Funding - Celgene (Inst) |
Travel, Accommodations, Expenses - Celgene |
|
|
Speakers' Bureau - Gilead Sciences; Novartis; Seagen; Spectrum Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |
|
|
No Relationships to Disclose |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Amgen; Kite, a Gilead company |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |
|
|
Employment - Kite, a Gilead company |
Leadership - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Amgen; Kite, a Gilead company |